Company news
Kezar Life Sciences, Inc. news in 2022
Kezar Life Sciences, Inc.'s news releases, calls and decks from 2022, newest first.
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022
November 13, 2022
Kezar Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022
Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at ASN’s Kidney Week 2022 Annual Meeting
November 2, 2022
Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis
October 2, 2022
Kezar Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022
Kezar Life Sciences Appoints Nick Mordwinkin as Chief Business Officer and Reports Updated Cash Position
July 10, 2022
Kezar Life Sciences Announces Positive Topline Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib for the Treatment of Patients with Lupus Nephritis
June 26, 2022
Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022
Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment of Dermatomyositis and Polymyositis
May 2, 2022
Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update
March 16, 2022
Decks in 2022
- Investor Day (June 2022)
Investor day · 27 slides · Jun 27, 2022